<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133117</url>
  </required_header>
  <id_info>
    <org_study_id>38RC16.070</org_study_id>
    <nct_id>NCT03133117</nct_id>
  </id_info>
  <brief_title>Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)</brief_title>
  <acronym>VISIOPERICENT</acronym>
  <official_title>Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire de Psychologie et NeuroCognition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this research is to study the cognitive and cerebral mechanisms of the&#xD;
      integration of central and peripheral visual information during normal and pathological aging&#xD;
      (ophthalmological patients with AMD and glaucoma) through fMRI studies. To assess the effect&#xD;
      of normal aging, research will be conducted on a group of young participants with normal&#xD;
      vision and a group of elderly participants with normal vision. Each participant will be&#xD;
      assessed once during an MRI (during which the brain activity and behavioral performance will&#xD;
      be measured). In order to evaluate the effect of pathological aging, research will be&#xD;
      conducted on AMD patients, glaucomatous patients, and age-matched controls (normal vision),&#xD;
      evaluated only once during an MRI examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy / control participants with normal vision will be volunteers, selected after&#xD;
      interview (inclusion assessment). Their recruitment will be carried out on the basis of&#xD;
      advertisements displayed at Grenoble Alpes University. Patients will be volunteers, selected&#xD;
      on the basis of their ophthalmological clinical record. Their recruitment will be done at the&#xD;
      Ophthalmology Clinic of the University Hospital of Grenoble (through Professor Florent&#xD;
      Aptel). For all the participants, a medical examination before MRI examination will be&#xD;
      carried out in the MRU unit of the CHU of Grenoble in order to verify the eligibility&#xD;
      criteria for contraindications to MRI and MRI scanning. The results of these examinations&#xD;
      will be communicated to the subjects prior to the expression of their consent directly or&#xD;
      through the doctor of their choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not enough patients&#xD;
  </why_stopped>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">May 25, 2018</completion_date>
  <primary_completion_date type="Actual">May 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of visual tasks in relation to the intensity of cerebral activity measured in fMRI</measure>
    <time_frame>One hour</time_frame>
    <description>Measurement of cerebral activity during visual tasks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Cerebral Bases of Central and Peripheral Visual Integration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Functional Magnetic Resonance Imaging (fMRI)</intervention_name>
    <description>Functional Magnetic Resonance Imaging (fMRI)</description>
    <arm_group_label>Cerebral Bases of Central and Peripheral Visual Integration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy / control participants: normal or normal corrected visual acuity&#xD;
&#xD;
          -  Patients with AMD: Diagnosis of AMD by the Clinique d'ophtalmologie of the CHU de&#xD;
             Grenoble&#xD;
&#xD;
          -  Patients Glaucoma: Diagnosis of glaucoma by the Clinique d'ophtalmologie of the CHU de&#xD;
             Grenoble&#xD;
&#xD;
          -  Affiliation to a social security scheme,&#xD;
&#xD;
          -  Informed consent signed,&#xD;
&#xD;
          -  Medical examination before participation in the MRI examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major unprotected persons unable to express their consent,&#xD;
&#xD;
          -  Major protected,&#xD;
&#xD;
          -  Significant hearing impairment,&#xD;
&#xD;
          -  Neuropsychiatric pathology past or present (except benign epilepsy),&#xD;
&#xD;
          -  Taking narcotics and / or drugs for neurocognitive purposes,&#xD;
&#xD;
          -  Existence of a general ailment (cardiac, respiratory, haematological, renal, hepatic,&#xD;
             cancer),&#xD;
&#xD;
          -  Other ophthalmic pathology that can affect visual function: cataract, retinal&#xD;
             detachment&#xD;
&#xD;
          -  Contra-indication to MRI:&#xD;
&#xD;
               1. Any subject with a vascular stent implanted less than 6 weeks before the&#xD;
                  examination.&#xD;
&#xD;
               2. Any subject carrying implanted biomedical material judged &quot;unsafe&quot; or &quot;unsafe&quot; in&#xD;
                  the list: http://www.mrisafety.com/TheList_search.asp.&#xD;
&#xD;
               3. Any acquisition procedure that does not comply with the conditions required by&#xD;
                  the &quot;conditional&quot; use in a subject carrying implanted biomedical material&#xD;
                  considered &quot;conditional&quot; in the list: http://www.mrisafety.com/TheList_search.&#xD;
                  Asp.&#xD;
&#xD;
               4. Any subject carrying an intra-ocular or intracranial ferromagnetic foreign body&#xD;
                  close to the nervous structures.&#xD;
&#xD;
               5. Any subject with biomedical equipment such as a cardiac, neuronal or sensory&#xD;
                  pacemaker (cochlear implant) or a ventricular bypass valve without medical and&#xD;
                  paramedical support trained to perform MRI in these subjects.&#xD;
&#xD;
               6. Non-Cooperative Subject&#xD;
&#xD;
               7. Metallic or electronic equipment incompatible with MRI examination, dental&#xD;
                  apparatus, claustrophobia, pacemaker or neurologic, non-magnetic non-magnetic&#xD;
                  vascular clip, metallic luster, diabetes&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Woman of childbearing age refusing to take the pregnancy test&#xD;
&#xD;
          -  Ongoing drug treatment that may affect brain activity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique Ophtalmologique Universitaire de Grenoble</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <state>CHU Albert Michallon - CS 10217</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

